387,718 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management acquired 387,718 Enliven Therapeutics shares worth approximately $19.7 million, giving it a 0.53% stake. Institutional investors collectively own 95.08% of the company.
• Analyst sentiment remains broadly positive: eight analysts rate ELVN a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $75.
• ELVN opened at $61.01, near its 52-week high of $62.32, but the company reported a quarterly loss of $0.49 per share, missing estimates by $0.10. Insiders sold 196,849 shares worth $11.3 million over the past three months.

ADAR1 Capital Management LLC bought a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 387,718 shares of the company's stock, valued at approximately $19,677,000. Enliven Therapeutics accounts for 0.9% of ADAR1 Capital Management LLC's holdings, making the stock its 25th biggest holding. ADAR1 Capital Management LLC owned approximately 0.53% of Enliven Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock worth $44,000 after purchasing an additional 594 shares in the last quarter. Invesco Ltd. increased its position in Enliven Therapeutics by 4.3% in the second quarter. Invesco Ltd. now owns 21,957 shares of the company's stock worth $440,000 after buying an additional 913 shares in the last quarter. BNP Paribas Financial Markets increased its position in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after buying an additional 930 shares in the last quarter. KBC Group NV bought a new position in shares of Enliven Therapeutics in the first quarter worth about $38,000. Finally, Swiss National Bank raised its stake in shares of Enliven Therapeutics by 1.7% in the fourth quarter. Swiss National Bank now owns 64,273 shares of the company's stock worth $990,000 after buying an additional 1,100 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the sale, the chief financial officer owned 40,036 shares of the company's stock, valued at approximately $2,345,308.88. This represents a 13.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the firm's stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director owned 41,884 shares of the company's stock, valued at $2,114,723.16. This trade represents a 19.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 196,849 shares of company stock worth $11,344,257 over the last three months. 3.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ELVN. Stifel Nicolaus boosted their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Guggenheim decreased their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. William Blair initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They set an "outperform" rating on the stock. JonesTrading upped their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday, June 29th. Finally, The Goldman Sachs Group increased their price objective on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $75.00.

Enliven Therapeutics Price Performance

NASDAQ ELVN opened at $61.01 on Wednesday. The stock has a market capitalization of $4.47 billion, a PE ratio of -36.53 and a beta of 0.27. The business has a 50 day simple moving average of $53.73 and a two-hundred day simple moving average of $42.53. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source